Trials & Tribulations Leveraging cutting-edge technology to address the impact of COVID-19 on cancer screening, diagnosis, and treatment February 04, 2022Vol.48 No.05By Gustaf Salford
Trials & Tribulations Approval of an immunotherapy for adjuvant NSCLC indication gives us new reasons for finding early-stage disease November 12, 2021Vol.47 No.42By Fred R. Hirsch
FreeTrials & Tribulations No longer “experimental”—Prostate cancer patients should have access to proton therapy November 05, 2021Vol.47 No.41By Shaakir Hasan
Trials & Tribulations Removing barriers to cancer care in underserved communities October 29, 2021Vol.47 No.40By Dany Habr
Trials & Tribulations A FLASH flood of research relating to ultra-high dose rate radiation therapy October 22, 2021Vol.47 No.39By Constantinos Koumenis and Amit Maity
Trials & Tribulations Converting Cox hazard ratios with Cox-TEL to improve interpretation of drug efficacy in checkpoint inhibitor trials September 10, 2021Vol.47 No.33By Yu Shyr
Trials & Tribulations Rogue drug maker first inflates the price of lomustine, then says No to Medicare coverage July 16, 2021Vol.47 No.28By Henry S. Friedman and John D. Lee
Trials & Tribulations Annals of Unintended Consequences: How FDA regulations undermine the biosimilar marketplace and the BPCIA June 18, 2021Vol.47 No.24By Howard S. Hochster and Michael P. Kane
FreeTrials & Tribulations Precision oncology must evolve to address health disparities June 04, 2021Vol.47 No.22By Brandon Mahal and Jeffrey Venstrom
Trials & Tribulations It’s time to rethink clinical trials in a post-pandemic world May 14, 2021Vol.47 No.19By Dana Dornsife
